Table 4.
Heteroresistance by demography, clinical data, and drug sensitivity results
| Variables | Total | Heteroresistance |
||
|---|---|---|---|---|
| N | % | |||
| Total | 123 | 12 | 9.8 | |
| Sex | Female | 48 | 7 | 14.6 |
| Male | 75 | 5 | 6.7 | |
| Age | < 15 | 3 | 0 | 0.0 |
| 15–24 | 45 | 5 | 11.1 | |
| 25–34 | 38 | 3 | 7.9 | |
| 35–44 | 18 | 1 | 5.6 | |
| 45–54 | 12 | 3 | 25.0 | |
| 55–64 | 6 | 0 | 0.0 | |
| 65+ | 1 | 0 | 0.0 | |
| HIV status | Negative | 82 | 7 | 8.5 |
| Positive | 33 | 5 | 15.2 | |
| Treatment history | Newly diagnosed | 72 | 9 | 12.5 |
| Retreatment | 51 | 3 | 5.9 | |
| Drug profiles | INH resistant | 60 | 10 | 16.7 |
| Overall MDR TB | 63 | 2 | 3.2 | |
| Rifampicin among MDR | 63 | 1 | 1.6 | |
| INH among MDR | 63 | 1 | 1.6 | |
| HIV negative INH resistant | 42 | 5 | 11.9 | |
| HIV Positive INH resistant | 13 | 5 | 38.5 | |
INH: isoniazid; MDR: multidrug resistant; TB: tuberculosis